Indivior PLC
LSE:INDV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
576.5
1 764
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Indivior PLC
Indivior PLC
Cost of Revenue
Indivior PLC
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Indivior PLC
LSE:INDV
|
Cost of Revenue
-$195m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cost of Revenue
-£8.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Cost of Revenue
-$8.7B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-5%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Cost of Revenue
-$543k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cost of Revenue
-$1.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-10%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cost of Revenue
-£331.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-14%
|
|
Indivior PLC
Glance View
Indivior PLC, a pivotal player in the pharmaceutical landscape, traces its roots back to a dedicated focus on addiction treatment. With an origin steeped in addressing opioid dependency, the company carved out a significant niche by developing and marketing medication-assisted treatments. At the heart of Indivior's success is its flagship product, Suboxone, which combines buprenorphine and naloxone to manage opioid addiction. This formulation, integral in combating withdrawal symptoms and reducing the allure of opioids, positioned Indivior as an innovator in an era when the opioid crisis commanded urgent attention. The company's revenue model leverages the growing need for comprehensive drug dependence solutions, primarily driven by its robust portfolio of treatment options. By relentlessly advocating for effective healthcare policies and ensuring substantial product availability, Indivior maintains its competitive edge. The company's strategy is not just confined to novel drug development, but also focuses on expanding treatment access globally, aligning profitability with public health imperatives. This dual commitment to innovation and societal impact ensures that Indivior remains a significant force in the healthcare sector, adeptly navigating the complexities of addiction treatment while generating sustainable financial growth.
See Also
What is Indivior PLC's Cost of Revenue?
Cost of Revenue
-195m
USD
Based on the financial report for Jun 30, 2024, Indivior PLC's Cost of Revenue amounts to -195m USD.
What is Indivior PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-7%
Over the last year, the Cost of Revenue growth was -13%. The average annual Cost of Revenue growth rates for Indivior PLC have been -18% over the past three years , -8% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
